Source link : https://www.newshealth.biz/health-news/more-evidence-ties-semaglutide-to-reduced-alzheimers-risk/
A new study provides real-world evidence to support the potential repurposing of glucagon-like peptide 1 receptor agonists (GLP-1 RAs), used to treat type 2 diabetes and obesity, for prevention of Alzheimer’s disease (AD). Adults with type 2 diabetes who were prescribed the GLP-1 RA semaglutide had a significantly lower risk for AD compared with their […]
Author : News Health
Publish date : 2024-10-24 14:41:47
Copyright for syndicated content belongs to the linked Source.